Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NeuroSense Therapeutics Ltd. Ordinary Shares
NRSN | US
1.10
USD0.03
2.80%
NRSN | US
About NeuroSense Therapeutics Ltd. Ordinary Shares
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.10
Open
1.08
High
1.10
Low
1.04
NeuroSense Therapeutics Ltd. a clinical-stage biotechnology company focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya Israel.
View LessNRSN | US
Risk
79.9
Sharpe
0.84
Luna's Score
42/100
Recommendation
Sell
Luna says (NRSN | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
98.2%1 month
79.9%3 months
89.7%6 months
91.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.15
Debt to equity
-0.02
Debt to assets
0.02
Ent. to EBITDA
-1.16
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-11.69M
MarketCap
21.79M
MarketCap(USD)
21.79M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-494.84
Short ratio
1.04
Short perc.
1.83
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.37
Range1M
0.47
Range3M
0.86
Volumes: Market Activity
Rel. volume
0.37
Price X volume
61.36K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.16 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.15 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 89.75 | - | Riskier |
| Debt to Equity | -0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 21.79M | - | Emerging |
